Cheung DG, et al. - The intention of the authors was to gauge the superiority of sacubitril/valsartan 200 mg (97/103 mg) to continued olmesartan 20 mg in reducing ambulatory systolic blood pressure (BP), among patients with mild to moderate essential hypertension uncontrolled with olmesartan 20 mg alone. The inference drawn was that sacubitril/valsartan was more effective and generally safe in such patients than with continued olmesartan.